---
title: "Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291191459.md"
description: "Needham analyst Serge Belanger reaffirmed a Buy rating on BioCryst with a $16 price target. He cited the company's strategic pivot to streamline R&D by exiting internal discovery and closing its Birmingham research center by end-2026, focusing instead on external innovation for rare diseases. Despite reduced operating expense assumptions, management maintains its 2026 revenue outlook for Orladeyo, signaling confidence in core growth and supporting the positive investment stance."
datetime: "2026-06-29T20:55:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291191459.md)
  - [en](https://longbridge.com/en/news/291191459.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291191459.md)
generator: "portal-rs"
---

# Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target

Serge Belanger, an analyst from Needham, maintained the Buy rating on BioCryst. The associated price target is $16.00.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Serge Belanger has given his Buy rating due to a combination of factors, including BioCryst’s decision to streamline its operations by exiting internal discovery work and closing its Birmingham, Ala. research center by the end of 2026. He views the pivot toward sourcing external innovation for rare disease assets as a more flexible, capital-efficient way to expand the company’s pipeline beyond its existing clinical-stage programs.

Belanger also highlights that, even with lower projected operating expenses, management is reaffirming its 2026 revenue outlook for Orladeyo and total company sales, signaling confidence in the core franchise’s growth trajectory. Reflecting these changes, he modestly reduces his operating expense assumptions while still seeing sufficient earnings power and upside potential to support a Buy rating and a $16 price target.

According to TipRanks, Belanger is a 5-star analyst with an average return of 15.0% and a 50.59% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Cytokinetics, and Oculis Holding.

### Related Stocks

- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)
- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)
- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [OCS.US](https://longbridge.com/en/quote/OCS.US.md)
- [OCSAW.US](https://longbridge.com/en/quote/OCSAW.US.md)

## Related News & Research

- [BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating](https://longbridge.com/en/news/291293304.md)
- [BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday](https://longbridge.com/en/news/294186102.md)
- [Jefferies Sticks to Its Buy Rating for Covista (CVSA)](https://longbridge.com/en/news/296118987.md)
- [Cantor Fitzgerald Sticks to Its Buy Rating for DeFi Development Corporation (DFDV)](https://longbridge.com/en/news/296108554.md)
- [25 rare and beautiful coins that are worth millions](https://longbridge.com/en/news/295960689.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**